Changes in Hong Kong stocks | Fu Hong Han Lin (02696) rose more than 3% and the anti-PD-1 monoclonal antibody H drug Hans appeared in “News Broadcast”

The Zhitong Finance App learned that Fuhong Hanlin (02696) rose more than 3%, with a cumulative increase of over 27% during the month. As of press release, it rose 3.73% to HK$70.95, with a turnover of HK$20.488,500.

According to the news, on the evening of August 8, China Central Radio and Television's CCTV-1 “News Broadcast” focused on China's pharmaceutical industry innovation breakthroughs in the first half of the year. The anti-PD-1 monoclonal H drug Hans Form (Slulizumab, European trade name: Hetronifly®) independently developed by Fuhong Hanlin appeared as a representative of an innovative domestic drug. The report mentioned, “This innovative drug for gastric cancer, the world's first 'chemotherapy', which was just launched this year, was authorized to obtain overseas revenue before it was marketed and sold, and has already been exported to many countries and regions around the world.”

Notably, the 2026 World Lung Cancer Conference (WCLC) will be held from September 12 to 15 in Seoul, South Korea. Fu Hong Hanlin will present a number of the latest research results of its innovative products at this conference, covering phase I research data on PD-L1ADCHLX43 in the field of thymic squamous cell carcinoma (TSCC), and 7 research data on the anti-PD-1 monoclonal H drug Hans form in the fields of broad-stage small cell lung cancer, limited-stage small cell lung cancer, and lung large cell neuroendocrine cancer.